The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics
View Course
Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis
This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight new and emerging CD-20 targeted therapeutics for the treatment of patients with multiple sclerosis (MS). The expert faculty, Dr. Mark Freedman, will first review current clinical trial data for CD-20 targeted therapies to improve long-term patient ...
View Course
Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach
View Course
Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder
This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight the use of anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). The expert faculty, Prof. Hans-Peter Hartung, will first analyze the methodologies for a timely and accurate diagnosis of NMOSD ...
View Course
Advances in the Management of Patients with Diabetic Kidney Disease in the Setting of Type 2 Diabetes
View Course
Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols
View Course
Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC
This CME program, derived from content presented at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland, will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Dr. Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers, and associated ...
View Course
Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis
This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will delve into a scientific update on Bruton tyrosine kinase inhibitors (BTKi) to improve outcomes for patients with multiple sclerosis (MS). The expert faculty, Dr. Benjamin Greenberg, will first review recent clinical trial data for BTK inhibitor therapeutics to treat patients with MS ...
View Course
Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis
This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will highlight strategies to identify and manage spasticity in patients with multiple sclerosis (MS). The expert faculty, Dr. Fred D. Lublin, will first review the unmet needs of multiple sclerosis patients with spasticity. Next, an analysis of current and emerging clinical trial data ...
View Course
Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer
This CME/CE program will highlight the application of poly (ADP-ribose) polymerase (PARP) inhibitors to improve outcomes for patients with advanced ovarian cancer. The expert faculty, led by Dr. Don Dizon, will first review updates to the National Comprehensive Care Network (NCCN) evidence-based guidelines. Next, an analysis of current and emerging clinical trial data of PARP Inhibitors will be discussed. Following, ...
View Course